Wird geladen...
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
OBJECTIVE: To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine. METHODS: A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients...
Gespeichert in:
| Veröffentlicht in: | Neurology |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Lippincott Williams & Wilkins
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6329331/ https://ncbi.nlm.nih.gov/pubmed/30446596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000006640 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|